|Table of Contents|

Clinical characteristics and risk factors of PPGL patients with bone metastases

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 02
Page:
332-336
Research Field:
Publishing date:

Info

Title:
Clinical characteristics and risk factors of PPGL patients with bone metastases
Author(s):
LI Longmin; GAO Hongbo; LI Yun; LI Zheng; LIU Haichun; ZHANG Xiaoyong; SHAO Yujun
Department of Radionuclide Treatment Center,Beijing Nuclear Industry Hospital,Beijing 102413,China.
Keywords:
pheochromocytoma; paraganglioma; bone metastasis; clinical features; risk factors
PACS:
R739.4
DOI:
10.3969/j.issn.1672-4992.2023.02.026
Abstract:
Objective:To explore the clinical characteristics of PPGLs with bone metastasisand the risk factors of earlybone metastasis（withinpostoperative 2 years）.Methods:The clinical data of 60 PPGL patients with bone metastasiswere analysedretrospectively.The risk factors and distribution differences of bonemetastasiswere analyzed.Results:Among 60 PPGL patients,14 cases(23.3%)had single bone metastasis and 46 cases(76.7%)hadmultiple bone metastases.The median time of bone metastasis was 84 months,and 15 cases(25%)had early bone metastasis.Univariate analysis showed that the age of PPGL patients was correlated with the time of bone metastasis(χ2=6.207,P=0.045).Early bone metastasis was more common in patients younger than 60 years old,the difference was statistically significant(χ2=25.600,P=0.000).A total of 353 lesions of bone metastases were found in PPGLs,including 79 lesions of thoracic vertebras.27 cases(45.0%)had complications related to bone metastasis,followed by bone pain(88.9%),numbness(51.9%),fracture(37.0%),paralysis(11.1%)and hypercalcemia(3.7%).Conclusion:Early bone metastasis is more common in patients younger than 60 years.Most bone metastasis occurs after two years of operation.Bone metastasis of PPGLsis usually multiple,of which the thoracic vertebra is the most frequent region.The most common complication is bone pain.

References:

［1］ 胡嘉禄,崔兆强,葛均波.嗜铬细胞瘤和副神经节瘤的诊断与临床管理［J］.中华高血压杂志,2020,28(02):179-186. HU JL,CUI ZQ,GE JB.Diagnosis and clinical management of pheochromocytoma and pa-raganglioma［J］.Chin-J Hypertens,2020,28(02):179-186.
［2］ JHA ABHISHEK,DE LUNA KRISTINE,BALILI CHARLENE ANN,et al.Clinical,diagnosticand treatment characteristics of SDHA-related metastatic pheochromocytoma and paraganglioma［J］.Front Oncol,2019,9:53.
［3］ 嗜铬细胞瘤和副神经节瘤诊断治疗的专家共识［J］.中华内分泌代谢杂志,2020,36(09):737-749. Expert consensus on the diagnosis and treatment of pheochromocytoma and paraganglioma［J］.Chinese Journal of Endocrinology and Metabolism,2020,36(09):737-749.
［4］ 邓建华,李汉忠.转移性嗜铬细胞瘤/副神经节瘤的临床诊断和预后［J］.协和医学杂志,2019,10(06):654-659. DENG JH,LI HZ.Clinical diagnosis and prognosis of metastatic pheochromocytoma and paraganglioma［J］.Medical Journal of Peking Union Medical College Hospital,2019,10(06):654-659.
［5］ ABOU CHAAR MOHAMAD K,KHANFERASEEL,ALMASRI NIDAL M,et al.Metastatic non-functional paraganglioma to the lung［J］.Journal of Cardiothoracic Surgery,2020,15(1):82.
［6］李云波,何伟,郭坤,等.18F-FDG PET/CT与99Tcm-MDP骨显像在恶性肿瘤骨转移中的检查效能比较［J］.现代肿瘤医学,2018,26(02):251-256. LI YB,HEW,GUO K,et al.The comparative study of 18F-FDG PET/CT and 99mTc-MDP bonescintigraphy in detecting bone metastasis［J］.Modern Oncology,2018,26(02):251-256.
［7］GURDIP K AZAD,GARY J,et al.Multi-technique imaging of bone metastases:spotlight on PET-CT［J］.Clinical Radiology,2016,71(7):620-631.
［8］ KIM JH,MOON H,NOH J,et al.Epidemiology and prognosis of pheochromocytoma/paraganglioma in Korea:a nationwide study based on the national health insurance service［J］.Endocrinol Metab(Seoul),2020,35(1):157-164.
［9］ FADIGALUCIA,SARAIVAJOANA,PAIVA ISABEL,et al.Thoracic spine metastasis presenting 18 years after complete resection of a phaeochromocytoma［J］.BMJ Case Reports,2019,12(8):e229621.
［10］ JOCHMANOVAIVANA,ABCEDE APRIL MELODY T,GUERRERO RUBY JANE S,et al.Clinical characteristics and outcomes of SDHB-related pheochromocytoma and paraganglioma in children and adolescents［J］.Journal of Cancer Research and Clinical Oncology,2020,146(4):1051-1063.
［11］ KIM KY,KIM JH,HONG AR,et al.Disentangling of malignancy from benign pheochromocytomas/paragangliomas［J］.PLoS One,2016,11(12):e0168413.
［12］ ILANCHEZHIAN M,JHA A,PACAK K,et al.Emerging treatments for advanced/metastatic pheochromocytoma and paraganglioma［J］.Curr Treat Options Oncol,2020,21(11):85.
［13］ 刘书中,宋桉,周熹,等.肾上腺嗜铬细胞瘤脊柱转移癌诊治的临床探讨［J］.中华内分泌代谢杂志,2018,34(9):805-808. LIU SZ,SONG A,ZHOU X,et al.The clinical discussion on diagnostic and treatment progress of metastatic spinal adrenal pheochromocytoma［J］.Chin J Endocrinol Metab,2018,34(9):805-808.
［14］ AYALA-RAMIREZ MONTSERRAT,PALMER J LYNN,HOFMANN MARIE-CLAUDE,et al.Bone metastases and skeletal-related events in patients with malignant pheochromocytoma and sympathetic paraganglioma［J］.The Journal of Clinical Endocrinology and Metabolism,2013,98(4):1492-1497.
［15］ ALEXANDER STEPHAN,KROISS.Current status of functional imaging in neuroblastoma,pheochromocytoma,and paraganglioma disease［J］.Wiener Medizinische Wochenschrift(1946),2019,169(1-2):25-32.
［16］ WANG H,CHENG JJ,OU XH.Recurrent malignant pheochromocytoma with unusual peritoneal carcinomatosis detected on 131I-MIBG SPECT/CT［J］.Clinical Nuclear Medicine,2021,46(1):40-42.
［17］ NAIMA KAL-BULUSHI,MOHEI-ELDINABOUZIED.Comparison of 18F-FDG PET/CT scan and 99mTc-MDP bone scintigraphy in detecting bone metastasis in head and neck tumors［J］.Nuclear Medicine Communications,2016,37(6):583-588.
［18］ HIROSHI WAKABAYASHI,ANRIINAKI,KENICHI YOSHIMURA,et al.A phase I clinical trial for 131I-meta-io-dobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma［J］.Scientific Reports,2019,9(1):155-158.
［19］ RAJEEV KASALIWAL,GAURAV MALHOTRA,ANURAG LILA,et al.Comparison of 131I-MIBG,68Ga-DOTANOCPET/CT and 18F-FDG PET/CT scans in a patient with extra adrenal paraganglioma associated with sdhb gene mutation［J］.Clinical Nuclear Medicine,2015,40(5):439-441.
［20］ 北美神经内分泌肿瘤学会和核医学与分子影像学会有关 177Lu-DOTATATE肽受体放射性核素治疗患者选择和合理应用共识［J］.中华核医学与分子影像杂志,2020,40(11):679-685. Consensus of the North American Society of Neuroendocrine Oncology and the Society for Nuclear Medicine and Molecular Imaging on the selection and rational use of 177Lu-DOTATATE peptide receptorradionuclide therapy in patients［J］.Chinese Journal of Nuclear Medicine and Molecular Imaging,2020,40(11):679-685.
［21］ HIROMASA TOMO,WAKABAYASHIHIROSHI,KAYANO DAIKI,et al.Prognostic factors for refractory pheochromocytoma and paraganglioma after 131I-metaiodobenzylguanidine therapy［J］.Annals of Nuclear Medicine,2022,36(1):61-69.
［22］ AGNIESZKA KOLASINSKA-CWIKCA,MARIOLAPL CZKOWSKA,JAROSLAW B CWIKL A,et al.A clinical efficacy of prrt in patients with advanced,nonresectable,paraganglioma-pheochromocytoma,related to SDHx gene mutation［J］.Journal of Clinical Medicine,2019,8(7):952.

Memo

Memo:
北京核工业医院院长基金（编号：YZJJ-2018-005）；中国宝原科研基金（编号：ZGBYKYJJ-2021-002）
Last Update: 1900-01-01